Phathom Pharmaceuticals Q4 revenue slightly beats expectations

Phathom Pharmaceuticals

26/02/2026 12:25

Overview

Biopharmaceutical firm's Q4 revenue slightly beat analyst expectations

Company reduced Q4 net loss compared to previous year

Strengthened financial position through $130 mln equity offering and debt modification

Outlook

Phathom expects operating profitability beginning in Q3 2026

Company forecasts FY 2026 net revenues of $320–$345 mln

Phathom anticipates gross margin of approximately 80% for FY 2026

Result Drivers

VOQUEZNA PRESCRIPTIONS - Q4 saw a 24% increase in VOQUEZNA prescriptions, driving revenue growth

SALES FORCE REALIGNMENT - Phathom completed sales force realignment, strengthening sales team and marketing initiatives

EXPENSE DISCIPLINE - Decrease in Q4 operating expenses due to reduced promotional and personnel costs

Company press release: ID:nGNX8rk2FB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$57.58 mln
$57.05 mln (9 Analysts)
Q4 Net Income
-$21.15 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $24.00, about 94.8% above its February 25 closing price of $12.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)